New CPT Code for the TIF Procedure Becomes Effective January 1, 2016
REDMOND, Washington – EndoGastric Solutions® (EGS), a leader in incisionless procedural therapy to treat Gastroesophageal Reflux Disease (GERD), announced today assignment of Category I Current Procedural Terminology (CPT®) code number 43210 with short form descriptor esophagogastroduodenoscopy, flexible, transoral with esophagogastric fundoplasty, partial or complete, includes duodenoscopy. The code and descriptor will be used for EGS’ Transoral Incisionless Fundoplication (TIF®) procedure for reflux starting January 1, 2016.
“We are pleased by the AMA’s decision to create a unique category I CPT code for the TIF procedure which represents another milestone for GERD patients,” said Skip Baldino, President and CEO of EndoGastric Solutions. “The AMA has acknowledged the significant clinical evidence, including two randomized clinical trials and multi-year outcome data for the TIF procedure.”
“We extend our deep appreciation to the AGA, ACG, ASGE, ASGS, and SAGES societies for their continued leadership efforts to advocate on behalf of their members and the patients they serve,” continued Baldino. “I am especially proud that EGS is the sole sponsor of multiple randomized-controlled trials and prospective registries demonstrating durable outcomes of transoral procedures for the treatment of GERD.”
The TIF procedure is backed by superior medical evidence from more than 50 peer-reviewed clinical publications encompassing over 40 study centers documenting outcomes on more than 800 unique study patients and features two randomized controlled trials:
RESPECT (Randomized EsophyX® vs. Sham/Placebo Controlled Trial) study, the first-ever blinded, randomized, sham- and placebo-controlled study for TIF® procedure. The study found that a majority of patients who underwent the TIF procedure experienced significant elimination of troublesome regurgitation and healed esophagitis compared to the sham – controlled group.1
TEMPO (TIF® versus Medical PPI Management of Refractory GERD symptoms) trial demonstrated elimination of daily troublesome regurgitation and atypical symptoms as evaluated by two validated instruments—Reflux Disease Questionnaire and Reflux Symptom Index; secondary outcomes included healing of esophagitis, normalization of esophageal acid exposure and PPI use in the TIF treated patients at 6 and 12 months.2
Over 17,000 TIF patients have been treated worldwide since EsophyX® device clearance in 2007. For more information, visit www.GERDHelp.com.
About Current Procedural Terminology (CPT®)
CPT codes are a listing of descriptive terms and identifying codes for reporting medical services and procedures. The purpose of CPT is to provide a uniform language that accurately describes medical, surgical, and diagnostic services, and thereby serves as an effective means for reliable nationwide communication among physicians and other healthcare providers, patients, and third parties. CPT® is registered trademark of the American Medical Association.